Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

Publisher Name :
Date: 31-Oct-2013
No. of pages: 112

GBI Research has released the pharmaceutical report “Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth”. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, GBI Research believes that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019.

Scope


  • An introduction to the treatments available for breast cancer, treatment algorithms and the contexts in which mAbs are clinically relevant to this type of cancer.

  • In-depth analysis of the five mAbs approved for breast cancer, with analysis of their safety, efficacy, treatment patterns and strengths and weaknesses. This includes a heat map comparing the drugs in terms of clinical trial results.

  • A comprehensive review of the pipeline for breast cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline for mAbs is analyzed on the basis of phase distribution, program type and molecular target, as is the entire pipeline for all molecule types.

  • Detailed analysis of pipeline drug clinical trials by trial size, trial duration and program failure rate for each molecule type and mechanism of action. Additionally, a detailed analysis of clinical trial endpoints is provided, detailing their importance in this disease area and their commercial relevance to currently marketed products.

  • Multi-scenario forecast data for the market is provided to 2019, which takes into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.

  • Discussion of the drivers and barriers for market growth

  • Complete analysis of licensing and co-development deals in this market, by year, value, molecule type, Phase and mechanism of action. Additionally, the international network of licensing deals in breast cancer is mapped out by geography.


Reasons to Buy

  • Understand the different indications for breast cancer, from early-stage to the metastatic disease

  • Grasp the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent, and the context of mAbs in the pipeline

  • Pinpoint the trends in clinical trial duration and size amongst clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for breast cancer therapeutics. Determine the risk associated with the development of mAbs compared to other molecule types.

  • Observe the shift in clinical trial endpoints by clinical Phase, and use this data to potentially influence any future developmental programs. Understand the importance of selecting the correct endpoints in the study of drugs for this disease.

  • Assess the potential clinical and commercial impact of recently-approved molecules on the breast cancer market and determine the potential revenues associated with the launch of a novel product, in addition to the level of competitiveness in the market.

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Monoclonal Antibodies Market in Breast Cancer to 2019 – Introduction 9
2.1 Symptoms 9
2.2 Etiology 9
2.3 Epidemiology 10
2.4 Pathophysiology 10
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 11
2.6.1 Classification 13
2.7 Treatment Options 13
2.7.1 Surgery and Radiation Therapy 13
2.7.2 Chemotherapy 14
2.7.3 Hormonal Therapies 15
2.7.4 Targeted Therapies 15
2.7.5 Resistance to Pharmacological Therapies 16
2.7.6 Treatment Guidelines 17
2.7.7 Measuring the Effectiveness of Treatment 19

3 Marketed Products 20
3.1 Herceptin (Trastuzumab) – Hoffmann La Roche 20
3.2 Avastin (Bevacizumab) – Hoffmann La Roche 23
3.3 Kadcyla (Trastuzumab Emtansine) – Hoffmann La Roche 25
3.4 Perjeta (Pertuzumab) – Hoffmann La Roche 26
3.5 Xgeva (denosumab) – Amgen 27
3.6 Heat Map for Marketed Products 28
3.7 Conclusion 30

4 Pipeline for Breast Cancer Monoclonal Antibody Therapeutics 31
4.1 Overall Pipeline 32
4.2 Mechanisms of Action 34
4.3 Clinical Trials 37
4.3.1 Attrition Rate 37
4.3.2 Clinical Trial Size 38
4.3.3 Duration 40
4.3.4 Clinical Trial End-points 42
4.4 Promising Drug Candidates in the Pipeline 44
4.4.1 CDX-011 (glembatumumab vedotin) – Celldex Therapeutics 44
4.4.2 Metmab (onartuzumab) – Hoffman La Roche 44
4.4.3 Hu3S193 – Recepta Biopharma 44
4.4.4 MM-121 – Merrimack Pharmaceuticals 45
4.4.5 IMC-18F1 (Icrucumab) – Eli Lilly 45
4.4.6 Rexomun (Ertumaxomab) – Fresenius Biotech 45
4.4.7 Medi-573 (Dusigitumab) – Medimmune 45
4.4.8 MK-0646 (Dalotuzumab) – Merck and Co 46
4.4.9 LY3012217 (Cixutumumab) - Eli Lilly 46
4.5 Conclusion 46

5 Market Forecast to 2019 48
5.1 Global 48
5.1.1 Treatment Usage Patterns 48
5.1.2 Market Size 49
5.2 US 50
5.2.1 Treatment Usage Patterns 50
5.2.2 Market Size 51
5.3 Canada 52
5.3.1 Treatment Usage Patterns 52
5.3.2 Market Size 53
5.4 Europe 54
5.4.1 Treatment Usage Patterns 54
5.4.2 Annual Cost of Therapy 55
5.4.3 Market Size 56
5.5 Japan 57
5.5.1 Treatment Usage Patterns 57
5.5.2 Market Size 58
5.6 Drivers and Barriers 59
5.6.1 Drivers 59
5.6.2 Barriers 59

6 Deals and Strategic Consolidations 60
6.1 R&D Licensing Agreements 60
6.1.1 Key Licensing Deals 63
6.2 Co-development Agreements 65
6.2.1 Key Deals 65

7 Appendix 68
7.1 References 68
7.2 References for Heat Map 73
7.3 All Pipeline Products, by Phase 74
7.3.1 Discovery 74
7.3.2 Preclinical 77
7.3.3 IND/CTA Filed and Phase I 89
7.3.4 Phase II 95
7.3.5 Phase III and Pre-Registration 102
7.4 Market Definitions 104
7.5 Abbreviations 105
7.6 Tabular Forecast Data 106
7.6.1 Global 106
7.6.2 US 106
7.6.3 Canada 106
7.6.4 UK 107
7.6.5 France 107
7.6.6 Germany 107
7.6.7 Italy 107
7.6.8 Spain 108
7.6.9 Japan 108
7.7 Research Methodology 109
7.7.1 Coverage 109
7.7.2 Secondary Research 109
7.8 Therapeutic Landscape 110
7.9 Epidemiology-Based Forecasting 110
7.10 Market Size by Geography 111
7.11 Geographical Landscape 112
7.12 Pipeline Analysis 112
7.13 Competitive Landscape 112
7.13.1 Expert Panel Validation 112
7.14 Contact Us 112
7.15 Disclaimer 112

List of Tables

Table 1: Market for mAbs in Breast Cancer, Global, TNM Staging, 2010–2013 11
Table 2: Market for mAbs in Breast Cancer, US, Disease Stage at Diagnosis and Five-year Relative Survival (%), 2013 12
Table 3: Market for mAbs in Breast Cancer, References for Heat Map (Figure 6) 73
Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 74
Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 77
Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase I and IND/CTA filed), 2013 89
Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 95
Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-Registration), 2013 102
Table 9: Market for mAbs in Breast Cancer, Global, Forecast Data, 2012–2019 106
Table 10: Market for mAbs in Breast Cancer, US, Forecast Data, 2012–2019 106
Table 11: Market for mAbs in Breast Cancer, Canada, Forecast Data, 2012–2019 106
Table 12: Market for mAbs in Breast Cancer, UK, Forecast Data, 2012–2019 107
Table 13: Market for mAbs in Breast Cancer, France, Forecast Data, 2012–2019 107
Table 14: Market for mAbs in Breast Cancer, Germany, Forecast Data, 2012–2019 107
Table 15: Market for mAbs in Breast Cancer, Italy, Forecast Data, 2012–2019 107
Table 16: Market for mAbs in Breast Cancer, Spain, Forecast Data, 2012–2019 108
Table 17: Market for mAbs in Breast Cancer, Japan, Forecast Data, 2012–2019 108

List of Figures

Figure 1 Market for mAbs in Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III 17
Figure 2: Market for mAbs in Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV 18
Figure 3: Market for mAbs in Breast Cancer, Global, Sales of Herceptin ($bn), 1999–2012 21
Figure 4: Market for mAbs in Breast Cancer, Global, Sales of Avastin ($bn), 2004–2012 24
Figure 5: Market for mAbs in Breast Cancer, Global, Aggregate Sales of Xgeva and Prolia ($m), 2010–2012 27
Figure 6: Market for mAbs in Breast Cancer, Global, Heat Map (Marketed Products) 29
Figure 7: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 32
Figure 8: Market for mAbs in Breast Cancer, Global, mAbs by Mechanism of Action, 2013 34
Figure 9: Market for mAbs in Breast Cancer, Global, mAbs by Mechanism of Action (Growth Factor Inhibitors), 2013 35
Figure 10: Market for mAbs in Breast Cancer, Global, mAbs by Molecular Target (Targeted Cytotoxic), 2013 36
Figure 11: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 37
Figure 12: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 38
Figure 13: Market for mAbs in Breast Cancer, Global, Clinical Trial Size, 2013 39
Figure 14: Market for mAbs in Breast Cancer, Global, Clinical Trial Duration, 2006–2013 40
Figure 15: Market for mAbs in Breast Cancer, Global, Clinical Trial Durations, 2006–2013 41
Figure 16: Market for mAbs in Breast Cancer, Global, Clinical Trial Endpoints for Phases II and III, 2006–2012 42
Figure 17: Market for mAbs in Breast Cancer, Global, Clinical Trial Endpoints for Phases II and III per Product, 2006–2012 43
Figure 18: Market for mAbs in Breast Cancer, Global, Treatment Usage Patterns, 2012–2019 48
Figure 19: Market for mAbs in Breast Cancer, Global, Market Size ($bn), 2012–2019 49
Figure 20: Market for mAbs in Breast Cancer, US, Treatment Patterns, 2012–2019 50
Figure 21: Market for mAbs in Breast Cancer, US, Market Size ($bn), 2012–2019 51
Figure 22: Market for mAbs in Breast Cancer, Canada, Treatment Usage Patterns, 2012–2019 52
Figure 23: Market for mAbs in Breast Cancer, Canada, Market Size ($m), 2012–2019 53
Figure 24: Market for mAbs in Breast Cancer, Top Five European Markets, Treatment Usage Patterns, 2012–2019 54
Figure 25: Market for mAbs in Breast Cancer, Top Five European Markets, Annual Cost of Therapy ($), 2012–2019 55
Figure 26: Market for mAbs in Breast Cancer, Top Five European Markets, Market Size ($m), 2012–2019 56
Figure 27: Market for mAbs in Breast Cancer, Japan, Treatment Usage Patterns, 2012–2019 57
Figure 28: Market for mAbs in Breast Cancer, Japan, Market Size ($m), 2012–2019 58
Figure 29: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (A) 60
Figure 30: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (B) 61
Figure 31: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (C) 62
Figure 32: Market for mAbs in Breast Cancer, Global, Co-development Deals (All Molecule Types) by Partner Country, 2006–2012 65
Figure 33: Market for mAbs in Breast Cancer, Global, Co-development Deals by Molecule Type, 2006–2012 66
Figure 34: GBI Research Market Forecasting Model 111

  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Current State of Blood Banking Market, Products, Technologies and Services
    The global blood banking and blood products market is expected to reach US$41.9 billion by 2020 with USA continuing to be the largest market worldwide. Asia-Pacific follows a close second with a projected CAGR of 9.1% during this period owing to the refining healthcare infrastructure and increase in the per capita healthcare expenditure. The major [...]
  • Surgical Robots Market 2016 Updates on Companies, Products and More
    Surgical robots are medical devices that assist surgeons in performing many types of complex procedures with more accuracy, flexibility and control than is possible with conventional techniques. The aim of surgical robots market players is to provide improved diagnostic skills, a less invasive and more comfortable experience for the patient, and the ability to do [...]
  • Phosphoinositide 3-Kinase Inhibitor (PI3k) Inhibitors - Pipeline Insights, 2016
    Published: 04-Jul-2016        Price: US 1750 Onwards        Pages: 160
    Note: This report will be delivered to the client in 48 hours DelveInsight's, "Phosphoinositide 3-Kinase Inhibitor (PI3k) Inhibitors-Pipeline Insights, 2016", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Phosphoinositide 3-Kinase Inhibitor (PI3k) Inhibitors. Report Highlights: ......
  • Natural Killer Cells- Competitive Landscape, Technology and Pipeline Analysis, 2016
    Published: 04-Jul-2016        Price: US 1950 Onwards        Pages: 155
    Note: This report will be delivered to the client in 48 hours DelveInsight's, "Natural Killer Cells- Competitive Landscape, Technology and Pipeline Analysis, 2016", report provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Natural Killer Cells. This report provides information on the therapeutic development based on the Natural Kil......
  • Global Solid Tumors Drugs Market 2016-2020
    Published: 24-Jun-2016        Price: US 2500 Onwards        Pages: 156
    The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors. Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, a......
  • United States Multiple Myeloma Drugs Industry 2016 Market Research Report
    Published: 21-Jun-2016        Price: US 3800 Onwards        Pages: 135
    The United States Multiple Myeloma Drugs Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Multiple Myeloma Drugs industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Multiple Myeloma Drugs market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions developmen......
  • Global Antibody-Drug Conjugate Industry 2016 Market Research Report
    Published: 21-Jun-2016        Price: US 2800 Onwards        Pages: 155
    The Global Antibody-Drug Conjugate Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Antibody-Drug Conjugate industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Antibody-Drug Conjugate market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' de......
  • Global DNA Repair Drugs Industry 2016 Market Research Report
    Published: 21-Jun-2016        Price: US 2800 Onwards        Pages: 150
    The Global DNA Repair Drugs Industry 2016 Market Research Report is a professional and in-depth study on the current state of the DNA Repair Drugs industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The DNA Repair Drugs market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status.......
  • Global Neutropenia Drugs Industry 2016 Market Research Report
    Published: 21-Jun-2016        Price: US 2800 Onwards        Pages: 151
    The Global Neutropenia Drugs Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Neutropenia Drugs industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Neutropenia Drugs market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status.......
  • Global Non Muscle Invasive Bladder Cancer Drugs Industry 2016 Market Research Report
    Published: 21-Jun-2016        Price: US 2800 Onwards        Pages: 157
    The Global Non Muscle Invasive Bladder Cancer Drugs Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Non Muscle Invasive Bladder Cancer Drugs industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Non Muscle Invasive Bladder Cancer Drugs market analysis is provided for the international market including development history, co......
  • Global Oligodendroglioma Drugs Industry 2016 Market Research Report
    Published: 21-Jun-2016        Price: US 2800 Onwards        Pages: 151
    The Global Oligodendroglioma Drugs Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Oligodendroglioma Drugs industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Oligodendroglioma Drugs market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' de......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs